You are here

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

Last updated on December 16, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bakersfield, California, 93309 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically or cytologically proven diagnosis of breast cancer

- Metastatic or locally recurrent disease that is, in the opinion of the investigator,
not amenable to resection or radiation therapy

- Patients with at least one measurable lesion as per RECIST

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Inflammatory breast cancer

- Prior treatment with VEGF inhibitors (unless in adjuvant setting at least 12 months
ago)

NCT00471276
Pfizer
Completed
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Androgen Receptor Positive Triple Negative Breast Cancer Advanced
NCT01889238
Females
18+
Years
Multiple Sites
Breast Neoplasms
NCT01176916
Females
0+
Years
Multiple Sites
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
NCT01945775
All Genders
18+
Years
Multiple Sites
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer
Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Neoplasms
Drug: sunitinib
sunitinib (Sutent), 37.5 mg, daily dosing
Other Name: Sutent, sunitinib
Experimental: 1
Intervention: Drug: sunitinib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
83
June 2010
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically proven diagnosis of breast cancer
  • Metastatic or locally recurrent disease that is, in the opinion of the investigator, not amenable to resection or radiation therapy
  • Patients with at least one measurable lesion as per RECIST

Exclusion Criteria:

  • Inflammatory breast cancer
  • Prior treatment with VEGF inhibitors (unless in adjuvant setting at least 12 months ago)
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00471276
A6181068
Yes
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now